^
    6d
    Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2024 --> Mar 2025
    Trial completion date • Metastases
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    10d
    Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (clinicaltrials.gov)
    P1, N=43, Recruiting, M.D. Anderson Cancer Center | Suspended --> Recruiting | N=21 --> 43
    Enrollment open • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cometriq (cabozantinib capsule)
    12d
    ADVL1622: Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (clinicaltrials.gov)
    P2, N=109, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2023 --> Sep 2024
    Trial completion date
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • AXL (AXL Receptor Tyrosine Kinase)
    |
    MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    17d
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    17d
    PAPMET: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed (clinicaltrials.gov)
    P2, N=152, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2023 --> Dec 2024 | Trial primary completion date: Oct 2020 --> Oct 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET mutation • MET expression
    |
    Xalkori (crizotinib) • Sutent (sunitinib) • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)
    17d
    Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, University of Washington | Recruiting --> Active, not recruiting | N=46 --> 6 | Trial completion date: Jul 2026 --> Jan 2027
    Enrollment closed • Enrollment change • Trial completion date • Combination therapy
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    24d
    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=125, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion
    |
    erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    24d
    Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (clinicaltrials.gov)
    P1, N=21, Suspended, M.D. Anderson Cancer Center | N=36 --> 21 | Recruiting --> Suspended
    Enrollment change • Trial suspension • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cometriq (cabozantinib capsule)
    28d
    Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of California, Irvine | Trial completion date: Jan 2024 --> Feb 2025 | Trial primary completion date: Dec 2023 --> Aug 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    RAS wild-type
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Lonsurf (trifluridine/tipiracil)
    1m
    Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (clinicaltrials.gov)
    P3, N=654, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    IFNA1 (Interferon Alpha 1)
    |
    Bavencio (avelumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    2ms
    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (clinicaltrials.gov)
    P2, N=99, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open • Surgery
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    2ms
    Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=35, Recruiting, University of California, Irvine | Trial completion date: Sep 2025 --> Sep 2027 | Trial primary completion date: Dec 2023 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    2ms
    Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Sep 2024 | Trial primary completion date: Jan 2024 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    2ms
    Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2024 --> Feb 2024
    Trial initiation date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    2ms
    Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer (clinicaltrials.gov)
    P2, N=84, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    2ms
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (clinicaltrials.gov)
    P2, N=224, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    2ms
    Cabozantinib and Nivolumab for Carcinoid Tumors (clinicaltrials.gov)
    P2, N=35, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    3ms
    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD276 (CD276 Molecule) • VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1) • CD4 (CD4 Molecule) • HHLA2 (HERV-H LTR-Associating 2)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    3ms
    BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study (clinicaltrials.gov)
    P2, N=150, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open • Tumor mutational burden • Metastases
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    4ms
    Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer (clinicaltrials.gov)
    P2, N=21, Not yet recruiting, Emory University | Initiation date: Dec 2023 --> Apr 2024
    Trial initiation date • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    4ms
    Cabozantinib for Adults With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=55, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    4ms
    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (clinicaltrials.gov)
    P2, N=99, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Surgery
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    4ms
    Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities (clinicaltrials.gov)
    P1/2, N=46, Recruiting, University of Washington | Trial completion date: Jan 2026 --> Jul 2026 | Trial primary completion date: Jan 2024 --> Jul 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    5ms
    CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)
    6ms
    Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Surgery • Metastases
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • IL6 (Interleukin 6) • CHGA (Chromogranin A) • CRP (C-reactive protein)
    |
    MET amplification • MET expression
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    6ms
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=117, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    7ms
    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery (clinicaltrials.gov)
    P2, N=99, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension • Surgery
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    7ms
    Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (clinicaltrials.gov)
    P1, N=152, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    PD-L1 expression • MET expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    7ms
    Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • paclitaxel • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    7ms
    Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    7ms
    Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Jun 2024
    Enrollment open • Trial initiation date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    7ms
    Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=41, Active, not recruiting, National Cancer Institute (NCI) | Completed --> Active, not recruiting
    Enrollment closed
    |
    AFP (Alpha-fetoprotein)
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    7ms
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=117, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    8ms
    Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    8ms
    Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer (clinicaltrials.gov)
    P2, N=21, Not yet recruiting, Emory University
    New P2 trial • Combination therapy • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    9ms
    Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=62, Recruiting, Yousef Zakharia | N=39 --> 62
    Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    9ms
    Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma (clinicaltrials.gov)
    P1/2, N=39, Recruiting, Yousef Zakharia | Trial completion date: Jul 2024 --> Dec 2026 | Trial primary completion date: Jul 2023 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    10ms
    Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University of California, Irvine | Recruiting --> Active, not recruiting | Trial completion date: Jun 2023 --> Nov 2024
    Enrollment closed • Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    10ms
    Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer (clinicaltrials.gov)
    P2, N=19, Active, not recruiting, Emory University | Trial completion date: May 2023 --> May 2025 | Trial primary completion date: May 2023 --> May 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    10ms
    Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of California, Irvine | Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Jan 2024 | Trial primary completion date: Mar 2023 --> Dec 2023
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    RAS wild-type
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Lonsurf (trifluridine/tipiracil)
    10ms
    Autologous Dendritic Cell Vaccine in Kidney Cancer (clinicaltrials.gov)
    P2a, N=42, Recruiting, Jodi Maranchie | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    CD31 (Platelet and endothelial cell adhesion molecule 1) • HES1 • NRP1 (Neuropilin 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine
    10ms
    CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    IL6 (Interleukin 6) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)